Vanda Reports Positive Tradipitant Trial Results In GLP-1 Induced Nausea And Vomiting

Vanda Pharmaceuticals reported positive topline results from a randomized, double-blind, placebo-controlled exploratory study of tradipitant (85 mg twice daily) in 116 overweight/obese adults given a 1 mg Wegovy dose: vomiting occurred in 29.3% of tradipitant-treated subjects versus 58.6% on placebo (≈50% relative reduction), and the key secondary endpoint—combined vomiting plus significant nausea—was 22.4% vs 48.3%. Safety was consistent with prior studies with no new adverse signals, and Vanda plans to initiate a Phase 3 program in H1 2026; tradipitant is also under FDA review for motion sickness with a PDUFA date of Dec. 30, 2025. If confirmed in larger trials, tradipitant could meaningfully improve adherence to GLP-1 therapies—which face 30–50% real-world discontinuation—creating a clear commercial adjunct opportunity; VANDA last closed at $4.40, up 1.15%, trading in a 12‑month range of $3.81–$5.70.

Analysis

Vanda Pharmaceuticals reported encouraging topline results from a randomized, double-blind, placebo-controlled exploratory study of tradipitant 85 mg twice daily in 116 overweight or obese adults who received a single 1 mg Wegovy injection after a one-week pretreatment. The trial met its primary endpoint with vomiting in 29.3% of tradipitant-treated subjects versus 58.6% on placebo (a ~50% relative reduction) and also met its key secondary endpoint (combined vomiting plus significant nausea 22.4% vs 48.3%).

Safety was described as consistent with prior studies with no new adverse signals reported, which supports tolerability in this small cohort. Given real-world GLP-1 discontinuation rates of 30–50%, these results imply tradipitant could meaningfully improve adherence and therefore represent a clear adjunct commercial opportunity if replicated in larger trials; tradipitant is also under FDA review for motion sickness with a PDUFA date of December 30, 2025.

The study is exploratory and limited by size (n=116), single-dose Wegovy simulation, and short follow-up; Vanda plans a Phase 3 program in H1 2026 and outcomes will hinge on pivotal design and regulatory acceptance. Market reaction to the readout was modest (VNDA closed $4.40, up 1.15%, 12‑month range $3.81–$5.70) and sentiment is moderately positive, indicating upside is catalyst-driven but clinical and regulatory binary risk remains material.

Key Decisions for Investors

• Consider a small, tactical long position in VNDA to gain exposure to the positive exploratory readout but limit sizing because the study is small and exploratory; await Phase 3 design and larger confirmatory data before increasing exposure
• Monitor the PDUFA date of December 30, 2025 for the motion‑sickness indication as a near‑term de‑risking catalyst and track initiation and protocol details of the planned Phase 3 program in H1 2026 for the GLP‑1 adjunct opportunity
• Employ downside protection (defined stop‑losses or hedges) given binary clinical and regulatory risk and watch for any new safety signals or differences in real‑world adherence metrics that would change the commercial case
• Use catalyst-driven trading around regulatory and Phase 3 milestones rather than a buy‑and‑hold approach given the modest market reaction to the topline and the stock's $3.81–$5.70 12‑month trading range